ASML's Q3 beat confirms near-term strength but fails to shift valuation or China risk

What happened

ASML reported Q3 revenue growth of 55% year-over-year and a 20% EPS beat, with gross margin expanding to 57.5% and operating margin exceeding 44%, demonstrating robust demand and pricing power in AI-driven chip investment. The results exceeded the company's own guidance for Q3 (€11-12 billion sales and 55-57% gross margin), though the revenue figure appears to be near the middle of that range rather than a massive upside surprise. Shares showed a muted reaction, indicating that investors had already priced in strong results and remain focused on longer-term concerns such as capacity expansion and China export controls. The company guided Q4 for continued sequential and year-over-year revenue growth, but noted that seasonality is a factor, which may temper near-term enthusiasm. Overall, the quarter confirms solid execution but does not address the key questions about whether ASML can convert its 2027 capacity plans into revenue without slippage or geopolitical disruption.

Implication

The Q3 results reinforce ASML's near-term earnings power and pricing, but the stock's muted reaction suggests the market is already discounting these achievements. Valuation remains demanding at roughly 59x P/E and 47x EV/EBITDA, leaving little room for error if execution or China restrictions worsen. Investors should watch for updates on the planned 30% capacity increases for low-NA EUV and DUV immersion in 2027, as any reduction would undermine the growth bridge. The China mix remains a wildcard: if tighter export controls force China revenue below 15% of sales without offsetting demand, gross margin and revenue could reset lower. Thus, while the quarter is positive, the risk-reward has not improved enough to justify adding to positions at current prices; a more attractive entry remains near $1,550, with trimming considered above $1,900.

Thesis delta

The Q3 beat confirms that near-term demand and execution are strong, reducing some uncertainty about the next couple of quarters. However, the muted stock reaction and unchanged longer-term challenges leave the core thesis intact: ASML is a high-quality business priced for perfection. Therefore, the WAIT rating remains appropriate; the beat does not warrant an upgrade without evidence that 2027 capacity plans are fully on track and China exposure is resolved.